Last reviewed · How we verify
NCT03501628: MPS
Leucine or Protein Supplementation and Resistance Training
NA trial testing Placebo in Skeletal Muscle in 89 participants. Completed in 17 August 2017.
17 May 2017
Quick facts
| Lead sponsor | Auburn University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 89 |
| Start date | 17 August 2016 |
| Primary completion | 17 May 2017 |
| Estimated completion | 17 August 2017 |
Drugs / interventions tested
- Placebo
- L-leucine + maltodextrin
- Whey protein concentrate
- Hydrolyzed whey protein concentrate
- Soy protein concentrate
Conditions studied
- Skeletal Muscle — all drugs for Skeletal Muscle →
Sponsor
Auburn University
Who can join
Adults 19 to 35, male only, with Skeletal Muscle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to determine the effects of L-leucine (LEU) or different protein supplements standardized to LEU (\~3.0 g/serving) on changes in body composition, strength, and histological attributes in skeletal muscle and adipose tissue. Seventy-five untrained, college-aged males (mean±SE; age=21±1 yr, body mass=79.2±0.3 kg) were randomly assigned to an isocaloric, lipid-, and organoleptically-matched maltodextrin placebo (PLA, n=15), LEU (n=14), whey protein concentrate (WPC, n=17), whey protein hydrolysate (WPH, n=14), or soy protein concentrate (SPC, n=15) group. Participants performed whole-body resistance training three days per week for 12 weeks while consuming supplements twice daily. Skeletal muscle and subcutaneous (SQ) fat biopsies were obtained at baseline (T1) and \~72 h following the last day of training (T39). Tissue samples were analyzed for changes in type I and II fiber cross sectional area (CSA), non-fiber specific satellite cell count, and SQ adipocyte CSA. On average, all supplement groups including PLA exhibited similar training volumes and experienced statistically similar increases in total body skeletal muscle mass determined by dual x-ray absorptiometry (+2.2 kg; time p=0.024) and type I and II fiber CSA increases (+394 µm2 and +927 µm2; time p\<0.001 and 0.024, respectively). Notably, all groups reported increasing Calorie intakes \~600-800 kcal/d from T1 to T39 (time p\<0.001), and all groups consumed at least 1.1 g/kg/d of protein at T1 and 1.3 g/kg/d at T39. There was a training, but no supplementation, effect regarding the reduction in SQ adipocyte CSA (-210 µm2; time p=0.001). Interestingly, satellite cell counts within the WPC (p\<0.05) and WPH (p\<0.05) groups were greater at T39 relative to T1. In summary, LEU or protein supplementation (standardized to LEU content) does not provide added benefit in increasing whole-body skeletal muscle mass or strength above PLA following 3 months of training in previously untrained college-aged males that increase Calorie intakes with resistance training and consume above the recommended daily intake of protein throughout training. However, whey protein supplementation increases skeletal muscle satellite cell number in this population, and this phenomena may promote more favorable training adaptations over more prolonged periods.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Skeletal muscle mitochondrial volume and myozenin-1 protein differences exist between high versus low anabolic responders to resistance training.
Roberts MD, Romero MA, Mobley CB, Mumford PW, et al · · 2018 · cited 40× · PMID 30065891 · DOI 10.7717/peerj.5338 -
Soy protein supplementation is not androgenic or estrogenic in college-aged men when combined with resistance exercise training.
Haun CT, Mobley CB, Vann CG, Romero MA, et al · · 2018 · cited 15× · PMID 30042516 · DOI 10.1038/s41598-018-29591-4
Verify or expand the search:
- PubMed search for NCT03501628
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skeletal Muscle
Currently open trials in the same condition.
- NCT07091500 — Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity · NA · recruiting
- NCT06677749 — Skeletal Muscle Myokine Response to Acute Eccentric Exercise · NA · recruiting
- NCT07481578 — Impact of Training Load on the Gut miCrobiome And Its Relation to exeRcise Performance, mUscle Phenotype, and markerS of · NA · recruiting
- NCT06666881 — Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients · NA · recruiting
- NCT04351113 — Targeting Oxidative Stress to Prevent Vascular and Skeletal Muscle Dysfunction During Disuse · NA · recruiting
Other Auburn University trials
Trials by the same sponsor.
- NCT05621538 — A Combined Neurofeedback-TMS Intervention for Alcohol Use Disorder · NA · recruiting
- NCT06274112 — Using TMS to Understand Neural Processes of Social Motivation · NA · recruiting
- NCT07489105 — Forge AHEAD: Feasibility of Yoga to Improve Cognitive Function · NA · recruiting
- NCT06565637 — Targeting Minority Stressors to Improve Eating Disorder Symptoms in Sexual Minority Individuals With Eating Disorders · Phase 1 · recruiting
- NCT06531863 — Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03501628 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Auburn University
- Last refreshed: 18 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03501628.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing